Up-regulation of nitric oxide synthase by estradiol in human aorticendothelial cells  by Hishikawa, Keiichi et al.
FEBS 15196 FEBS Letters 360 (1995) 291-293 
Ul -regulation of nitric oxide synthase by estradiol in human aortic 
endothelial cells 
Keiichi Hishikawa a, Toshio Nakaki b'*, Takeshi Marumo a, Hiromichi Suzuki a, Ryuichi Kato b, 
Takao Sarutaa 
"Department ofInternal Medicine, Keio University School of Medicine, 35 Shinanomaehi, Shinjuku-ku, Tokyo 160, Japan 
bDepartment of Pharmacology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160, Japan 
Received 1 February 1995 
Abstract We have examined the effects of sex hormones on 
calcinm-dependent NO production and protein levels of NO syn- 
thase in cultured human aortic endothelial cells, which were 
treated with various doses of 17~-estradiol and testosterone for 
8-48 h. Treatment with 17~-estradiol enhanced calcium-depend- 
ent NO production, but testosterone had exerted no effect. West- 
ern blot using monoclonal anti-human endothelial NO synthase 
antibody clarified that increased NO production by 17~-estradiol 
treatment was accompanied by increased NO synthase protein. 
Our results provide evidence that human endothelial NO synthase 
can be regulated by estrogens. 
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1. Introduction 
Nitric oxide (NO) is a cellular messenger with numerous 
biological functions, including regulation of vascular tone, cel- 
lular signaling in the brain, and killing of pathogens in nonspe- 
cific immune responses. NO is derived from the guanidino 
nitrogen atom of L-arginine through a reaction catalyzed by 
NO synthase (NOS) (EC 1.14.13.39). NOS was originally di- 
vided into two functional classes based on sensitivity to cal- 
cium, but differences in properties and differential inhibitor/ 
substrate specificity suggest that there are three major forms of 
NOS. This has recently been confirmed by the cloning and 
characterization f three distinct NOS cDNAs [1-3]. This per- 
mits the definitive classification of the gene products so far 
characterized in this way as neuronal NOS (nNOS), endothelial 
NOS (eNOS) and inducible NOS (iNOS) [4]. 
Many epidemiological studies have demonstrated that there 
is a gender difference in the morbidity associated with hyper- 
tension. In some animal experiments, administration of estra- 
diol has been reported to increase ndothelium-dependent r - 
laxation [5,6], and female rabbit aorta has been reported to 
release a higher basal level of NO than that of male [7]. These 
results uggest that eNOS might be regulated by sex hormones. 
But the effect of estrogen on eNOS mRNA level is controversial 
in bovine [8] and porcine [9] endothelial cells. Recently, Weiner 
et al. reported that calcium-dependent NOS was induced dur- 
ing pregnancy in guinea pigs [10]. The aim of this study is to 
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clarify, whether, at physiological levels, sex hormones modulate 
NO production and eNOS protein in human aortic endothelial 
cells. We tested this hypothesis in cultured human aortic endo- 
thelial cells by measuring calcium-dependent NO production 
and level of eNOS protein in both presence and absence of sex 
hormones. 
2. Materials and methods 
2.1. Cell Culture 
Human aortic endothelial cells (HAEC) were obtained from Krabo 
(Osaka, Japan). Cells were seeded onto a collagen-coated 24-multiwell 
plate or 35 mm dish (Corning, NY, USA), at an initial density of 1 x 105 
cells/cm 2,containing 500/.tl or 2 ml of Endomedia (Immuno Bio Labo- 
ratory, Gunma, Japan), 10% fetal calf serum (Mitsubishi-kasei, Tokyo, 
Japan). Cells were used between passages 2 and 4. 
2.2. Measurement of NO production 
After treatment, each well was washed 3 times with 1 ml of Hanks' 
solution and then incubated at 37°C for 30 rain, before stimulation with 
1 /~M ionomycin. The ionomycin-stimulated NO production from 
HAEC was measured as the levels of nitrite/nitrate, oxidized products 
of nitric oxide, using an automated system TCI-NOX 1000 (Tokyo 
Kasei Kogyo Co., Tokyo, Japan) based on the Griess reaction [11]. 
Nitrite/nitrate values at time 0, just after ionomycin stimulation, were 
subtracted from cumulative values, during the 30 min ionomycin stim- 
ulation period, obtained from the same wells. 
2.3. Western blot 
eNOS protein was analyzed by Western blot with anti-human eNOS 
antibody (Transduction Laboratory, Kentucky, USA). The antibody 
was used at 250 times dilution. This antibody is specific for human 
eNOS: the Transduction Laboratory confirmed that it does not cross- 
react with nNOS and iNOS. The confluent cells in 35 mm dishes (1 × 106 
cells/dish) were washed with Hank's solution and then lysed in 200 ~1 
of solution containing 10% glycerol, 2.3% SDS, Tris-HC1 (pH 6.8) 62.5 
mM, 0.01% Bromophenol blue and 5% mercaptoetbanol. The lysate 
was then heated at 100°C for 5 min. Whole cell lysates which contained 
50/tg of protein were subjected to SDS-PAGE (7.5% gradient). The 
separated proteins were electrophoretically transferred tomembranes, 
then incubated with anti-human eNOS antibody for 1 h as previously 
described [12]. 
2.4. Statistical nalysis 
The data are expressed as the means and S.E.M.s in the text and 
figures. Statistical significance was assessed by t-test, and a P value less 
than 0.05 was considered significant. 
3. Results 
Without stimulation, NO production was below 50 pmol/h/ 
105 cells. In acute experiments, HAEC were stimulated with 
ionomycin along with 17fl-estradiol (2 × 104 pg/ml) or testoster- 
one (2 × 104 pg/ml). Neither hormone showed significant effects 
on ionomycin-stimulated NO production (Fig. 1A, time 0). 
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Fig. 1. Time courses of 17fl-estradiol and testosterone effects on cal- 
cium-dependent NO production (A) and human endothelial cNOS pro- 
tein (B). (A) Cells were treated with either 2 x 104 pg/ml of 17fl-estradiol 
or testosterone for the indicated times. After sex hormone treatments, 
NO production was stimulated by ionomycin (1/aM) and accumulated 
nitrite and nitrate were measured. Nitrite and nitrate values at time 0 
were subtracted from cumulative values after ionomycin stimulation for 
30 min obtained from the same wells. Closed circles indicate no treat- 
ment. Open circles indicate treatment with 2 x 104 pg/ml of 17fl-estra- 
diol. Open triangles indicate treatment with 2 x 10 4 pg/ml of testoster- 
one. Means + S.E.M. are shown (n = 6). *P < 0.05 compared with t e 
no treatment value at time 0. (B) eNOS protein was analyzed by West- 
ern blot with the anti-human eNOS antibody (lanes 14, 50 mg of 
protein per lane). Data are representative of 4 experiments. Lane 1, 
control; lane 2, 2 x 10 4 pg/ml of 17fl-estradiol for 12 h; lane 3, 24 h; lane 
4,48 h. 
Next, we examined the long term effects of treatment with 
17fl-estradiol r testosterone on ionomycin-stimulated NO pro- 
duction. Pretreatment for more than 8 h with 17fl-estradiol 
significantly increased the ionomycin-stimulated NO produc- 
tion, while testosterone showed no effect even at 48 h (Fig. 1A). 
Western blot using anti-human eNOS antibody also clarified 
that pretreatment with 17fl-estradiol increased eNOS protein 
in a time dependent manner (Fig. 1B). 
Fig. 2A shows the dose response curve of 17fl-estradiol n 
ionomycin-stimulated NO production. Above 200 pg/ml, 17fl- 
estradiol significantly increased calcium-dependent NO pro- 
duction in a dose dependent manner. The results of Western 
blot (Fig. 2B) also support the notion that 17fl-estradiol in- 
creased NO production by increases in eNOS protein. 
To clarify the mechanism of induction of eNOS, HAEC were 
pretreated with tamoxifen (1 pM) for 4 h. The 17fl-estradiol 
(2 x 104 pg/ml) was then added to the medium and the culture 
was continued for another 48 h. As a negative control, L-N a- 
monomethyl-arginine (LNMMA) was added just before iono- 
mycin stimulation. LNMMA almost completely inhibited iono- 
mycin-stimulated NO production both in control and 17fl- 
estradiol treatment. Tamoxifen itself showed no effect on iono- 
mycin-stimulated NO production, but showed significant inhi- 
bition on estrogen-induced increase in ionomycin-stimulated 
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NO production. (Fig. 3). Subtracting the value of 17/~-estradiol 
treatment from no treatment, he inhibitory effect of tamoxifen 
was calculated to be about the half that of the estrogen-induced 
increase in ionomycin-stimulated NO production. 
4. Discussion 
Our studies demonstrate for the first time that eNOS in- 
creases in response to 17fl-estradiol inhuman aortic endothelial 
cells. Moreover, physiological concentrations of 17fl-estradiol, 
which range from 2 to 2 x 104 pg/ml [13], cause this induction. 
The highest concentration occurs during pregnancy, reaching 
approximately 2 × 104 pg/ml. This suggests that a protective 
effect on the cardiovascular system, exerted by 17fl-estradiol 
supplementation, is related to eNOS induction in vivo. Our 
results may also explain why pre-menopausal women are less 
prone than men to coronary artery disease and why there is an 
increased prevalence of cardiovascular disease in post-meno- 
pausal women. 
Human eNOS has been clarified at the gene level, and some 
regulatory sequences including a shear stress responsive le- 
ment, heavy meal responsive elements, and an AP-2 binding site 
have been reported in the 5' flanking region of the human 
eNOS gene [14]. However, in human eNOS, the existence of an 
estrogen responsive element (5 ' -CAGGTCAGAGTGACCTG-  
3') [15] remains controversial. Two left half palindromic sites 
of an estrogen responsive el ment (GGTCA) exist at -1,347 
and -444 and four right half sites (TGACC) exist at -1,198, 
-774, -463 and -310, but the complete sequence has yet to be 
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Fig. 2. Dose-response curves of 17fl-estradiol effects on calcium-de- 
pendent NO production (A) and increased eNOS protein (B). (A) Cells 
were treated with various doses of 17fl-estradiol for 48 h. After 17,8- 
estradiol treatment, NO production was stimulated with ionomycin (1 
#M) and accumulated nitrite and nitrate were measured. Nitrite and 
nitrate values at time 0 were subtracted from cumulative values after 
ionomycin stimulation for 30 min obtained from the same wells. Means 
+ S.E.M. are shown (n = 6). *P<0.05 compared with the value at time 
0. (B) eNOS protein was analyzed by Western blot with the anti-human 
eNOS antibody (lanes 14, 50 gg of protein per lane). Data are repre- 
sentative of 4 experiments. Lane 1 indicates control; lane 2, 2 × 102 
pg/ml of 17fl-estradiol for 48 h; lane 3, 2 × 103; lane 4, 2 × 10 4. 
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Fig. 3. Effects of NG-monomethyl-L-arginine and tamoxifen on estra- 
dioMnduced NO production. NOx was measured as the nitrite and 
nitrate production resulting from stimulation with 1/.tM of ionomycin 
in each case. Est indicates treatment with 17fl-estradiol (2 x 10  4 pg/ml) 
for 48 h. LNMMA indicates treatment with 500 pM of LNMMA just 
before stimulated by ionomycin. TAM indicates treatment with 1/tM 
tamoxifen for 48 h. When cells were treated with both tamoxifen and 
17fl-estradiol, tamoxifen was added 4 h before addition of 17fl-estra- 
diol. Means + S.E.M. are shown (n = 6). *P < 0.05 compared with the 
value of no treatment cells. **P < 0.05 compared with the value of 
17fl-estradiol treated cells. Abbreviations are: LNMMA, NG-monom - 
ethyl-L-arginine; TAM, tamoxifen. 
clarified. Recently Rosseli et al. reported that estrogen supple- 
mentation increased NO production in vivo, based on the re- 
sults of a two year clinical study [16]. Taken together with our 
data, these results [10,16] suggest that the partial sequences may 
have functional roles as responsive lements in eNOS. 
We used tamoxifen to investigate the roles of estrogen recep- 
tors. As compared to LNMMA,  the tamoxifen inhibition was 
weaker though still significant. This may be explained by ta- 
moxifen being a partial agonist of estrogen receptors. We can- 
not exclude the possibility that 17fl-estradiol exerts its effect by 
binding to its receptors, or, by modulating the calcium-calmod- 
ulin system in a manner similar to that of nNOS [17]. 
eNOS plays important roles in maintaining homeostasis of 
the cardiovascular system. It is, therefore, important to clarify 
the regulation of eNOS, but it has not been thoroughly investi- 
gated. Cytokines have been reported to down-regulate mRNA 
of eNOS [18,19], but to augment NO production [18,19]. There 
are also discrepancies among reports about the effects of estro- 
gen on mRNA levels of eNOS between bovine and porcine 
endothelial cells [8,9]. To clarify these discrepancies, it was 
293 
necessary to examine the effect of estrogen on protein levels of 
eNOS in human endothelial cells. Herein, we have demon- 
strated that estrogen up-regulates eNOS proteins in human 
aortic endothelial cells and our results also support he report 
about pregnant guinea pigs [10]. These findings encourage fur- 
ther studies of sex hormones for therapeutic intervention i  
NO-mediated changes in vascular tone in man. 
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